Ming-Shien Wen

Ming-Shien Wen

Auto-generated profile, based on publicly available information

Ming-Shien Wen

Division of Cardiology, Chang Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Obesity Research & Clinical Practice
Verified
Journal Article
Closed access
CLChien-Hung Liao
Chien-Hung Liao
CWChao-Yung Wang
Chao-Yung Wang
KLKeng-Hau Liu
Keng-Hau Liu
YLYu-Yin Liu
Yu-Yin Liu
MWMing-Shien Wen
Ming-Shien Wen
TYTa-Sen Yeh
Ta-Sen Yeh

28 February 2019 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
MOMinami Ohara
Minami Ohara
YSYasuhiko Suzuki
Yasuhiko Suzuki
SSSaki Shinohara
Saki Shinohara
IGInna Y. Gong
Inna Y. Gong
CSCrystal L. Schmerk
Crystal L. Schmerk
HTHarumi Takahashi
Harumi Takahashi

29 October 2024 in JACC: Asia
Verified
Journal Article
Open access
CCChieh-Yu Chang
Chieh-Yu Chang
CCChun-Chi Chen
Chun-Chi Chen
MTMing-Lung Tsai
Ming-Lung Tsai
MHMing-Jer Hsieh
Ming-Jer Hsieh
TCTien-Hsing Chen
Tien-Hsing Chen
DCDong-Yi Chen
Dong-Yi Chen
Few studies have incorporated echocardiography and laboratory data to predict clinical outcomes in heart failure with preserved ejection fraction (HFpEF). This study aimed to use machine learning to find predictors of heart failure (HF) hospitalization and cardiovascular (CV) death in HFpEF. From the Chang Gung Research Database in Taiwan, 6,092 HFpEF patients (2,898 derivation, 3,194 validation) identified between 2008 and 2017 were followed until 2019. A random survival forest model, using 58 variables, was developed to predict the composite outcome of HF hospitalization and CV death. During 2.9-year follow-up, 37.7% of derivation and 36.0% of validation cohort patients experienced HF hospitalization or CV death. The study identified 15 predictive indicators, including age ≥65 years, B-type natriuretic peptide level ≥600 pg/mL, left atrium size ≥46 mm, atrial fibrillation, frequency of HF hospitalization within 3 years, body mass index <30 kg/m2, moderate or severe mitral regurgitation, left ventricular (LV) posterior wall thickness of <10 or ≥13 mm, dysnatremia, LV end-diastolic dimension of <40 or ≥56 mm, uric acid level ≥7 mg/dL, triglyceride level of <70 or ≥200 mg/dL, blood urea nitrogen level ≥20 mg/dL, interventricular septum thickness of <11 or ≥20 mm, and glycated hemoglobin (HbA1c) level of <6% or ≥8%. The random survival forest model demonstrated robust external generalizability with an 86.9% area under curve in validation. Machine learning identified 15 predictors of HF hospitalization and CV death in HFpEF patients, helping doctors identify high-risk individuals for tailored treatment.

9 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CWChun-Yu Wei
Chun-Yu Wei
MWMing-Shien Wen
Ming-Shien Wen
CCChih-Kuang Cheng
Chih-Kuang Cheng
YSYi-Jing Sheen
Yi-Jing Sheen
TYTsung-Chieh Yao
Tsung-Chieh Yao
PKPui-Yan Kwok
Pui-Yan Kwok
Incorporating pharmacogenetics into clinical practice promises to improve therapeutic outcomes by optimizing drug selection and dosage based on genetic factors affecting drug response. A key advantage of PGx-guided therapy is to decrease the likelihood of adverse events. To evaluate the clinical impact of PGx risk variants, we performed a retrospective study using genetic and clinical data from the largest Han Chinese cohort, comprising 486,956 individuals, assembled by the Taiwan Precision Medicine Initiative. We found that nearly all participants carried at least one genetic variant that could affect drug response, with many carrying multiple risk variants. Here we show the detailed analyses of four gene-drug pairs, azathioprine ( NUDT15 / TPMT ), clopidogrel ( CYP2C19 ), statins ( ABCG2 / CYP2C9 / SLCO1B1 ), and NSAIDs ( CYP2C9 ), for which sufficient data exists for statistical power. While the results validate previous findings that PGx risk variants are significantly associated with drug-related adverse events or ineffectiveness, the excess risk of adverse events or lack of efficacy is small compared to that found in those without the PGx risk variants, and most patients with PGx variants do not suffer from adverse events. Our results point to the complexity of implementing PGx in clinical practice and the need for integrative approaches to optimize precision medicine.

22 January 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
YHYi-Ting Hwang
Yi-Ting Hwang
HLHui-Ling Lee
Hui-Ling Lee
CLCheng-Hui Lu
Cheng-Hui Lu
PCPo-Cheng Chang
Po-Cheng Chang
HWHung-Ta Wo
Hung-Ta Wo
CCChung-Chuan Chou
Chung-Chuan Chou
Aims: Curved M-mode images of global strain (GS) and strain rate (GSR) provide sufficiently detailed spatiotemporal information of deformation mechanics. This study investigated whether a deep convolutional neural network (CNN) could accurately classify these images in patients with atrial fibrillation (AF) who underwent radiofrequency catheter ablation (RFCA) with different outcomes.Methods and Results: We retrospectively evaluated 606 consecutive patients who underwent RFCA for drug-refractory AF. Patients were divided into AF-free (n = 443) and AF-recurrent (n = 163) groups. Transthoracic echocardiography was performed within 24 h after RFCA. Left atrial curved M-mode speckle-tracking images were acquired from randomly selected 163 patients in AF-free group and 163 patients in AF-recurrent group as the dataset for deep CNN modeling. We used the ReLu activation function and repeatedly performed CNN model for 32 times to evaluate the stability of hyperparameters. Logistic regression models with the left atrial dimension, emptying fraction, and peak systolic GS as predictor variables were used for comparisons. Images from the apical 2-chamber (2-C) and 4-chamber (4-C) views had distinct features, leading to different CNN performance between settings; of them, the “4-C GS+4-C GSR” setting provided the highest performance index values. All four predictor variables used for logistic regression modeling were significant; however, none of them, individually or in any combined form, could outperform the optimal CNN model.Conclusion: The novel approach using deep CNNs for learning features of left atrial curved M-mode speckle-tracking images seems to be optimal for classifying outcome status after AF ablation.

1 January 2016 in Circulation Journal
Verified
Journal Article
Open access
DCDong-Yi Chen
Dong-Yi Chen
CMChun-Tai Mao
Chun-Tai Mao
MTMing-Lung Tsai
Ming-Lung Tsai
MHMing-Jer Hsieh
Ming-Jer Hsieh
YLYu-Sheng Lin
Yu-Sheng Lin
Tien-Hsing ChenTien-Hsing Chen
Tien-Hsing Chen
Data on the cardiovascular (CV) outcomes of drug-eluting stents (DES) vs. bare-metal stents (BMS) in patients with acute myocardial infarction (AMI) under dialysis are limited. We analyzed the data from 42,592 AMI patients in the Taiwan National Health Insurance Research Database between 1 January 2007 and 31 December 2011. A total of 984 AMI patients under dialysis were selected as the study cohort. We evaluated the clinical outcomes by comparing 492 subjects who had DES to 492 matched subjects who had BMS. The primary composite outcomes, which included recurrent MI, coronary revascularization and CV death, were significantly lower in the DES group than in the BMS group (41.7% vs. 47.6%, hazard ratio (HR), 0.77; 95% confidence interval (CI), 0.63-0.92, P=0.005) after mean 1.2 years. The patients who received DES had a lower risk of recurrent MI (HR, 0.63; 95% CI, 0.45-0.90), CV death (HR, 0.74; 95% CI, 0.56-0.98) and all-cause mortality (HR, 0.74; 95% CI, 0.61-0.89) than those who used BMS, but a similar risk of major bleeding (HR, 0.99; 95% CI, 0.69-1.42, P=0.952) and ischemic stroke (HR, 1.15; 95% CI, 0.66-2.01, P=0.631). Among AMI patients on dialysis undergoing percutaneous coronary interventions, DES implantation significantly reduced the risk of recurrent MI, CV death and all-cause mortality compared with BMS implantation.